Logo image of ZYME

ZYMEWORKS INC (ZYME) Stock Fundamental Analysis

NASDAQ:ZYME - Nasdaq - US98985Y1082 - Common Stock - Currency: USD

14.005  -0.24 (-1.72%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ZYME. ZYME was compared to 556 industry peers in the Biotechnology industry. While ZYME seems to be doing ok healthwise, there are quite some concerns on its profitability. ZYME is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZYME had negative earnings in the past year.
In the past year ZYME has reported a negative cash flow from operations.
ZYME had negative earnings in 4 of the past 5 years.
In the past 5 years ZYME reported 4 times negative operating cash flow.
ZYME Yearly Net Income VS EBIT VS OCF VS FCFZYME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

ZYME's Return On Assets of -27.00% is fine compared to the rest of the industry. ZYME outperforms 70.68% of its industry peers.
The Return On Equity of ZYME (-35.38%) is better than 73.74% of its industry peers.
Industry RankSector Rank
ROA -27%
ROE -35.38%
ROIC N/A
ROA(3y)-9.3%
ROA(5y)-23.17%
ROE(3y)-12.22%
ROE(5y)-33.15%
ROIC(3y)N/A
ROIC(5y)N/A
ZYME Yearly ROA, ROE, ROICZYME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZYME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYME Yearly Profit, Operating, Gross MarginsZYME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

ZYME does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ZYME has less shares outstanding
Compared to 5 years ago, ZYME has more shares outstanding
The debt/assets ratio for ZYME has been reduced compared to a year ago.
ZYME Yearly Shares OutstandingZYME Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ZYME Yearly Total Debt VS Total AssetsZYME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

ZYME has an Altman-Z score of 3.59. This indicates that ZYME is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ZYME (3.59) is better than 74.64% of its industry peers.
ZYME has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ZYME has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: ZYME outperforms 48.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.59
ROIC/WACCN/A
WACC9.77%
ZYME Yearly LT Debt VS Equity VS FCFZYME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 4.71 indicates that ZYME has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.71, ZYME is in line with its industry, outperforming 51.08% of the companies in the same industry.
A Quick Ratio of 4.71 indicates that ZYME has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.71, ZYME is in line with its industry, outperforming 52.34% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.71
Quick Ratio 4.71
ZYME Yearly Current Assets VS Current LiabilitesZYME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

7

3. Growth

3.1 Past

ZYME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.05%, which is quite impressive.
Looking at the last year, ZYME shows a very strong growth in Revenue. The Revenue has grown by 84.86%.
Measured over the past years, ZYME shows a very strong growth in Revenue. The Revenue has been growing by 20.93% on average per year.
EPS 1Y (TTM)29.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)84.86%
Revenue growth 3Y41.91%
Revenue growth 5Y20.93%
Sales Q2Q%170.29%

3.2 Future

The Earnings Per Share is expected to grow by 8.28% on average over the next years. This is quite good.
ZYME is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.09% yearly.
EPS Next Y-13.54%
EPS Next 2Y-7.36%
EPS Next 3Y-7.23%
EPS Next 5Y8.28%
Revenue Next Year19.53%
Revenue Next 2Y26.82%
Revenue Next 3Y13.4%
Revenue Next 5Y20.09%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ZYME Yearly Revenue VS EstimatesZYME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
ZYME Yearly EPS VS EstimatesZYME Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZYME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZYME. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYME Price Earnings VS Forward Price EarningsZYME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYME Per share dataZYME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

A cheap valuation may be justified as ZYME's earnings are expected to decrease with -7.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.36%
EPS Next 3Y-7.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZYME!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYMEWORKS INC

NASDAQ:ZYME (7/21/2025, 12:03:00 PM)

14.005

-0.24 (-1.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07
Inst Owners100.4%
Inst Owner Change0.02%
Ins Owners0.06%
Ins Owner Change0%
Market Cap1.05B
Analysts84
Price Target22.84 (63.08%)
Short Float %9.51%
Short Ratio14.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-89.49%
Min EPS beat(2)-206.99%
Max EPS beat(2)28.01%
EPS beat(4)3
Avg EPS beat(4)-39.8%
Min EPS beat(4)-206.99%
Max EPS beat(4)28.01%
EPS beat(8)5
Avg EPS beat(8)-23.8%
EPS beat(12)8
Avg EPS beat(12)-11.45%
EPS beat(16)11
Avg EPS beat(16)-5.24%
Revenue beat(2)1
Avg Revenue beat(2)-2%
Min Revenue beat(2)-32.69%
Max Revenue beat(2)28.69%
Revenue beat(4)2
Avg Revenue beat(4)-1.9%
Min Revenue beat(4)-32.69%
Max Revenue beat(4)28.69%
Revenue beat(8)4
Avg Revenue beat(8)-3.64%
Revenue beat(12)6
Avg Revenue beat(12)0.6%
Revenue beat(16)7
Avg Revenue beat(16)-2.61%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.48%
EPS NQ rev (3m)-1.47%
EPS NY rev (1m)-2.88%
EPS NY rev (3m)7.54%
Revenue NQ rev (1m)6.54%
Revenue NQ rev (3m)7.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)14.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.24
P/FCF N/A
P/OCF N/A
P/B 3.23
P/tB 3.39
EV/EBITDA N/A
EPS(TTM)-1.27
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.01
OCFYN/A
SpS1.25
BVpS4.34
TBVpS4.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27%
ROE -35.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-9.3%
ROA(5y)-23.17%
ROE(3y)-12.22%
ROE(5y)-33.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.92%
Cap/Sales 2.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.71
Quick Ratio 4.71
Altman-Z 3.59
F-Score5
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)85.81%
Cap/Depr(5y)108.99%
Cap/Sales(3y)4.19%
Cap/Sales(5y)15.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y-13.54%
EPS Next 2Y-7.36%
EPS Next 3Y-7.23%
EPS Next 5Y8.28%
Revenue 1Y (TTM)84.86%
Revenue growth 3Y41.91%
Revenue growth 5Y20.93%
Sales Q2Q%170.29%
Revenue Next Year19.53%
Revenue Next 2Y26.82%
Revenue Next 3Y13.4%
Revenue Next 5Y20.09%
EBIT growth 1Y27.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.75%
EBIT Next 3Y-11.56%
EBIT Next 5YN/A
FCF growth 1Y-172.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-164.84%
OCF growth 3YN/A
OCF growth 5YN/A